@article {8170,
	title = {Ifosfamide and paclitaxel salvage chemotherapy for advanced epithelial ovarian cancer},
	journal = {Annals of Oncology},
	volume = {8},
	year = {1997},
	note = {Cited By :10Export Date: 21 February 2017},
	month = {1997},
	pages = {195 - 197},
	abstract = {Objective: To evaluate the efficacy and toxicity of the combination of ifosfamide (1.5 g/m2 i.v. on days 1, 2, 3) and paclitaxel (135 mg/m2 i.v. over 3 hours on day 3) with G-CSF (5 μg/kg/d subcutaneously, days 7-11) administered every 3 weeks on an outpatient basis in patients with advanced epithelial ovarian cancer previously treated with platinum-based chemotherapy. Patients and methods: Thirty-five consecutive patients were treated, 12 of whom had previously received two regimens. Twelve of the 35 were defined as platinum-resistant and 23 as potentially platinum-sensitive. Results: Fifteen patients (43\%; 95\% CI: 26\%-61\%) achieved objective responses, five of them complete and ten partial. Objective responses occurred in 17\% of the platinum-resistant patients and in 57\% of those with potentially platinum-sensitive disease. The median duration of response was seven months and the median overall survival 11 months. The treatment was well tolerated and only 15\% of the patients developed grade 3 or 4 neutropenia. With the exception of alopecia there were no other grade 3 or 4 toxicities. Conclusions: The combination of ifosfamide and paclitaxel was well tolerated and showed activity in patients with ovarian cancer who had previously undergone platinum-based chemotherapy.},
	keywords = {Ifosfamide, Ovarian cancer, Paclitaxel},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-0031048959\&doi=10.1023\%2fA\%3a1008293415079\&partnerID=40\&md5=1b16e4f3ec929257c22ff3d99c1d2cc3},
	author = {Dimopoulos, M.A. and Papadimitriou, C. and Gennatas, C. and Akrivos, T. and Vlahos, G. and Voulgaris, Z. and Diacomanolis, E. and Athanassiades, P. and Mihalas, S.}
}
